capecitabine has been researched along with Dihydropyrimidine Dehydrogenase Deficiency in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (12.73) | 29.6817 |
| 2010's | 29 (52.73) | 24.3611 |
| 2020's | 19 (34.55) | 2.80 |
| Authors | Studies |
|---|---|
| Burns, K; Findlay, M; Helsby, N; Porter, D; Strother, M | 1 |
| Essapen, S; Howlett, S; Wang, L | 1 |
| Aoki, H; Araki, H; Arata, T; Katsuda, K; Kimura, Y; Minagi, H; Nagahisa, S; Ogawa, T; Tanakaya, K; Taniguchi, F; Watanabe, M | 1 |
| Akutsu, D; Fukuda, S; Hagiwara, Y; Ikeda, N; Inagaki, Y; Kobayashi, M; Moriwaki, T; Narasaka, T; Niisato, Y; Onoda, T; Suzuki, H; Tange, Y; Tomisaki, R; Tsuchiya, K; Tsuji, M; Yamada, K; Yamada, T; Yamamoto, Y | 1 |
| Henry, NL; Hertz, DL; Koo, K; Pasternak, AL; Sahai, V | 1 |
| Brooks, GA; Busam, JA; Daly, AT; Tapp, S; Tosteson, ANA | 1 |
| Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C | 1 |
| Barin-Le Guellec, C; Boige, V; Chouchana, L; Ciccolini, J; Etienne-Grimaldi, MC; Loriot, MA; Narjoz, C; Pallet, N; Taieb, J; Thomas, F; Zaanan, A | 1 |
| Bilić, I; Božina, N; Ganoci, L; Lešnjaković, L; Mucalo, I; Pleština, S; Šimičević, L | 1 |
| Bergmann, TK; Damkier, P; Ewertz, M; Feddersen, S; Fruekilde, PBN; Holm, HS; Paulsen, NH; Pfeiffer, P; Qvortrup, C | 1 |
| Abdalla, H; Adem, FMK; Alnuhait, M; AlSagoor, T; Bryson, S; Bustami, R; Karbani, G; Sukkarieh, HH | 1 |
| Arrivé, C; Brice, A; Chirica, C; Farneti, D; Fonrose, X; Frenoux, C; Gautier-Veyret, E; Jacquet, E; Roth, G; Stanke-Labesque, F; Thomas, F | 1 |
| Brac-de-la-Perriere, C; Brice, A; Dalenc, F; De Maio D'Esposito, E; Eche-Gass, A; Mathevet, Q; Poumeaud, F; Thomas, F | 1 |
| Azevedo, PG; Bastos-Rodrigues, L; Bicalho, MA; Coelho, LG; Cunha-Junior, GF; De Marco, L; Magno, LAV | 1 |
| Ciccolini, J; De Victor, B; Hilaire, V; Krache, A; Lacarelle, B; Lucas, M; Marin, C; Palmaro, C; Quaranta, S; Solas, C; Ugdonne, R | 1 |
| Abarca-Zabalía, J; García-Alfonso, P; García-González, X; Kaczmarczyk, B; López-Fernández, LA; Pachón, V; Robles, L; Salvador-Martín, S; Sanjurjo-Sáez, M; Thomas, F; Vaz, Á | 1 |
| Bm Claes, K; Borbath, I; Casneuf, V; Demey, W; Geboes, KP; Haufroid, V; Van den Eynde, M; Verheezen, Y; Verstraete, AG | 1 |
| Choi, YH; Keller, D; Kim, RB; Legan, RM; Lenehan, J; Mailloux, J; Medwid, S; Nevison, S; Panuganty, V; Povitz, BL; Sarma, S; Schwarz, UI; Siebring, V; Teft, WA; Welch, S; Wigle, TJ; Winquist, E | 1 |
| Etienne-Grimaldi, MC; Gautier-Veyret, E; Haufroid, V; Launay, M; Maillard, M; Narjoz, C; Pallet, N; Royer, B; Schmitt, A; Thomas, F; Tron, C | 1 |
| Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E | 1 |
| Cats, A; Goorden, SMI; Henricks, LM; Meijer, J; Polstra, AM; Rosing, H; Schellens, JHM; Siemerink, EJM; van Kuilenburg, ABP; Zoetekouw, L | 1 |
| Hu, EH; Keung, YK; Yu, D; Zurayk, M | 1 |
| Ciccolini, J; Lacarelle, B; Milano, G | 1 |
| Barin-Le-Guellec, C; Becquemont, L; Bobin-Dubigeon, C; Boyer, JC; Broly, F; Ciccolini, J; Etienne-Grimaldi, MC; Evrard, A; Fonrose, X; Harle, A; Hennart, B; Lafay-Chebassier, C; Loriot, MA; Masskouri, F; Milano, G; Narjoz, C; Paci, A; Picard, N; Poinsignon, V; Quaranta, S; Royer, B; Schmitt, A; Thomas, F; Verstuyft, C; Wozny, AS | 1 |
| Penel, N | 1 |
| Bamat, MK; Garcia, RAG; Saydoff, JA; von Borstel, RW | 1 |
| Cecchin, E; Dreussi, E; Fiocco, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Meulendijks, D; Peters, FP; Schellens, JHM; Swen, JJ; Toffoli, G | 1 |
| Arita, S; Koike, N; Oshima, Y; Takeuchi, T; Watanabe, H | 1 |
| Beijnen, JH; Cats, A; de Boer, A; Deenen, MJ; Henricks, LM; Meulendijks, D; Schellens, JHM; van Merendonk, LN | 1 |
| Awan, S; Frankel, AE; Hosein, PJ; Khushman, M; Maharjan, AS; McMillin, GA; Nelson, C; Pai, S; Patel, GK; Singh, AP; Taylor, WR; Wang, B | 1 |
| André, T; Barin-Le-Guellec, C; Bouché, O; Boyer, JC; Carni, P; Ciccolini, J; Delaloge, S; Étienne-Grimaldi, MC; Faroux, R; Guigay, J; Le Malicot, K; Legoux, JL; Loriot, MA; Malka, D; Masskouri, F; Michel, P; Seitz, JF; Thariat, J; Thomas, F | 1 |
| Amylidi, AL; Angelaki, A; Aravantinos, G; Boumpoucheropoulos, S; Fildissis, G; Lampropoulou, DI; Laschos, K; Nanou, E; Nasioulas, G; Papadopoulou, E; Soupos, N; Zidianakis, V | 1 |
| Dołegowska, B; Ostapowicz, A | 1 |
| Albini, A; Banzi, M; Boni, C; Casali, B; Farnetti, E; Focaccetti, C; Magnani, E; Nicoli, D; Savoldi, L | 1 |
| Caudle, KE; Diasio, RB; Klein, TE; McLeod, HL; Schwab, M; Swen, JJ; Thorn, CF | 1 |
| Ikeda, H; Kato, H; Kodera, M; Mizuno, K; Oishi, M; Seshimo, K; Toshima, T; Yamamura, M; Yamashita, Y | 1 |
| Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M | 1 |
| Nagai, K; Ohara, Y; Okuda, Y; Yamamoto, M | 1 |
| Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC | 1 |
| Alés-Díaz, I; Benavides-Orgaz, M; Bermejo-Pérez, MJ; Durán-Ogalla, G; Galeote-Miguel, AM; Rodelo-Haad, LE | 1 |
| Bathini, V; Kodali, S; Rava, P; Tipirneni, E | 1 |
| Aliev, A; Beijnen, JH; Cats, A; de Graaf, H; Henricks, LM; Jacobs, BA; Meijer, J; Meulendijks, D; Rozeman, L; Schellens, JH; van Kuilenburg, AB | 1 |
| Dezentjé, V; Dobritzsch, D; Hennekam, RC; Hertz, JM; Jansen, RL; Knegt, LC; Los, M; Maurer, D; Meijer, J; Meinsma, R; van Huis-Tanja, LH; van Kampen, RJ; van Kuilenburg, AB; Zoetekouw, L | 1 |
| Gelderblom, H; Guchelaar, HJ; Lunenburg, C; Swen, JJ | 1 |
| Moore, S | 1 |
| Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C | 1 |
| Abali, H; Disel, U; Gürkut, O; Kaleağasi, H; Mertsoylu, H; Ozyilkan, O; Saif, MW | 1 |
| Boot, H; Cats, A; Deenen, MJ; Schellens, JH; Terpstra, WE | 1 |
| Beijnen, JH; Cats, A; Deenen, MJ; Mandigers, CM; Schellens, JH; Soesan, M; Terpstra, WE | 1 |
| Haanen, JB; Hooiveld, EA; van Kuilenburg, AB; Westermann, AM | 1 |
| Boyer, JC; Ciccolini, J; Dahan, L; Dales, JP; Durand, A; Evrard, A; Lacarelle, B; Mercier, C; Milano, G; Richard, K; Seitz, JF | 1 |
| Diasio, R; Saif, MW | 1 |
| Diasio, R; Elfiky, A; Saif, MW | 1 |
| Ciccolini, J; Mercier, C | 1 |
| Autret-Leca, E; Blasco, H; Boisdron-Celle, M; Bougnoux, P; Calais, G; Ciccolini, J; Le Guellec, C; Tournamille, JF | 1 |
12 review(s) available for capecitabine and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Rectal Neoplasms | 2022 |
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Pharmacogenomic Variants | 2023 |
Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Middle Aged; Mutation; Uridine | 2019 |
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; France; Humans; Neoplasms; Phenotype; Practice Guidelines as Topic; Pyrimidines; Uracil | 2018 |
[A Case of Colon Cancer with DPD Deficiency That Showed Severe Myelosuppression by CapeOX Adjuvant Chemotherapy after Colon Resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Middle Aged; Myeloid Cells; Oxaliplatin | 2018 |
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Neoplasms; Uridine | 2020 |
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Mutation; Neoplasms; Polymorphism, Single Nucleotide; RNA, Messenger; Uracil | 2012 |
[A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
Topics: Aged; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Fluorouracil; Humans; Male; Neutropenia; Thrombocytopenia | 2013 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Colitis; Contraindications; Deoxycytidine; Diagnosis, Differential; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Ileitis; Mutation; Neoplasm Metastasis; Triple Negative Breast Neoplasms | 2014 |
Unanticipated toxicity to capecitabine.
Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Drug Monitoring; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Nursing Assessment; Oncology Nursing; Pharmacogenetics; Risk Factors; Safety; Vomiting | 2009 |
Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms; Polymorphism, Genetic | 2006 |
43 other study(ies) available for capecitabine and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Gastrointestinal Neoplasms; Genotype; Humans; Male; New Zealand; Risk Factors | 2021 |
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom.
Topics: Antimetabolites, Antineoplastic; Cancer Care Facilities; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Male; Prospective Studies; Retrospective Studies; United Kingdom | 2022 |
[A Case of Colon Cancer with Suspected DPD Deficiency Causing Severe Adverse Effects following Adjuvant Chemotherapy with Capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Humans | 2021 |
Survey of US Medical Oncologists' Practices and Beliefs Regarding
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Oncologists | 2022 |
Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Topics: Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit Analysis; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans | 2022 |
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms; Renal Insufficiency; Uracil | 2022 |
Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Denmark; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Gastrointestinal Neoplasms; Genotype; Humans; Uracil | 2023 |
Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Saudi Arabia | 2023 |
Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Retrospective Studies | 2023 |
Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.
Topics: Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Genotype; Humans; Phenotype | 2023 |
Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry.
Topics: Antimetabolites, Antineoplastic; Black People; Brazil; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Healthy Volunteers; Humans; Male; Mutation; Neoplasms; Prevalence | 2019 |
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Chromatography, High Pressure Liquid; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Spectrophotometry, Ultraviolet; Uracil | 2020 |
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Computer Simulation; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Retrospective Studies; Uracil | 2020 |
Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
Topics: Antimetabolites, Antineoplastic; Belgium; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; Tegafur | 2022 |
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Topics: Aged; Antimetabolites, Antineoplastic; Canada; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Heterozygote; Humans; Male; Medical Oncology; Middle Aged; Neoplasms; Pharmacogenomic Testing; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Retrospective Studies | 2021 |
Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation.
Topics: Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2021 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotype; Hospitalization; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Predictive Value of Tests; Prospective Studies; Thymidylate Synthase; Uracil; Young Adult | 2017 |
Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Genetic Testing; Genotype; Humans; Middle Aged; Prognosis | 2018 |
PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine.
Topics: Antibiotics, Antineoplastic; Biomarkers; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Humans; Uracil | 2017 |
[Requirement of DPD deficiency screening before prescription of fluoropyrimidines].
Topics: Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2018 |
Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Topics: Acetates; Animals; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Drug Overdose; Female; Fluorouracil; Mice; Survival Analysis; Uridine | 2018 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Clinical Trials as Topic; Databases, Factual; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Genetic Predisposition to Disease; Genotype; Hematologic Diseases; Humans; Inactivation, Metabolic; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Young Adult | 2018 |
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Male; Matched-Pair Analysis; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Retrospective Studies | 2019 |
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gastrointestinal Neoplasms; Genetic Association Studies; Genotyping Techniques; Heterozygote; Homozygote; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Severity of Illness Index; Young Adult | 2019 |
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biology; Biomedical Research; Breast Neoplasms; Capecitabine; Digestive System Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; France; Genotype; Health Care Surveys; Humans; Oncologists; Otorhinolaryngologic Neoplasms; Pharmacovigilance; Practice Guidelines as Topic; Pyrimidines; Reimbursement Mechanisms | 2019 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Heterozygote; Humans; Male; Mutation; Patient Selection; Polymerase Chain Reaction | 2013 |
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genotype; Humans; Incidental Findings; Male; Risk Assessment; Sex Factors; Tegafur | 2013 |
[Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; Male; Sigmoid Neoplasms | 2015 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Uracil | 2015 |
Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Humans | 2014 |
Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Fluorouracil; Humans; Male; Middle Aged; Rectal Neoplasms | 2017 |
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); DNA, Complementary; Female; Fluorouracil; Gene Expression; Genetic Variation; Genotype; Haplotypes; Humans; Introns; Male; Middle Aged; Mutation; Neoplasms; Precision Medicine; Retrospective Studies | 2016 |
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Amplification; HEK293 Cells; Humans; Male; Middle Aged; Models, Molecular; Mutation; Mutation, Missense; Neoplasms; Pharmacogenomic Variants; RNA Splicing; Sequence Deletion | 2017 |
Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Topics: Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Fluorouracil; Humans; Male; Middle Aged | 2017 |
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Fluorouracil; Humans; Intensive Care Units; Male | 2010 |
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Atrophy; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Erythema; Fluorouracil; Foot; Functional Laterality; Hand; Humans; Male; Stomach Neoplasms | 2010 |
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Prodrugs; Rectal Neoplasms; Tegafur | 2010 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Female; Fluorouracil; Genetic Testing; Genotype; Humans; Male; Middle Aged; Neoplasms; Risk Assessment; Tegafur | 2012 |
[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Humans; Leukocytes, Mononuclear; Middle Aged; Mutation; Neoplasm Recurrence, Local | 2004 |
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); DNA Primers; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Tomography, X-Ray Computed | 2006 |
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms | 2006 |
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Paresthesia; Prodrugs; Rectal Neoplasms; Syndrome | 2006 |
A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Drug Monitoring; Female; Fluorouracil; Humans; Polymorphism, Genetic | 2008 |